SUMMARY
SUMMARY

Lipopolysaccharide (LPS) binding protein (LBP) is
an acute-phase protein that initiates an immune response after recognition of bacterial LPS. Here, we report the crystal structure of murine LBP at 2.9 Å resolution. Several structural differences were observed between LBP and the related bactericidal/permeability-increasing protein (BPI), and the LBP C-terminal domain contained a negatively charged groove and a hydrophobic ''phenylalanine core.'' A frequent human LBP SNP (allelic frequency 0.08) affected this region, potentially generating a proteinase cleavage site. The mutant protein had a reduced binding capacity for LPS and lipopeptides. SNP carriers displayed a reduced cytokine response after in vivo LPS exposure and lower cytokine concentrations in pneumonia. In a retrospective trial, the LBP SNP was associated with increased mortality rates during sepsis and pneumonia. Thus, the structural integrity of LBP may be crucial for fighting infections efficiently, and future patient stratification might help to develop better therapeutic strategies.
INTRODUCTION
Recognition of microbial products evokes the innate immune response, which provides the first line of defense against invading pathogens (Medzhitov and Janeway, 1997) . Lipopolysaccharide (LPS) Binding Protein (LBP) is a 50 kDa polypeptide secreted into the bloodstream as a 58-60 kDa glycosylated protein, and it is induced mainly in the liver as class I acute phase protein Tobias et al., 1986) . LBP mediates potent innate immune responses by recognizing LPS originating from different Gram-negative bacteria (Mathison et al., 1992; Rietschel et al., 1996) . It can monomerize LPS multimers, which enables cellular recognition via CD14 and the toll-like receptor 4 (TLR4)-MD-2 receptor complex by promoting TLR4-dimerization followed by rapid signal transduction (Hailman et al., 1994; Schumann et al., 1990; Tsukamoto et al., 2010) . LBP can also detoxify LPS by transferring it to lipoproteins to limit inflammation (Lamping et al., 1998; Wurfel et al., 1994; Zweigner et al., 2001) , and this function is particularly important in the lung (Bingle and Craven, 2004) . LPB also binds lipopeptides (LP) present in almost all types of bacteria and mycoplasm, and thus might be viewed as a soluble pattern recognition molecule (Schrö der et al., 2004; Schumann, 2011) .
LBP belongs to a rapidly evolving protein family, found in many species, termed palate, lung, and nasal epithelium clone (Plunc) (Bingle and Craven, 2004) . Among this family, Bactericidal/ permeability-increasing protein (BPI) is the closest homolog of LBP (Tobias et al., 1988; Weiss et al., 1978) . BPI can also bind LPS and is found mainly in the granules of neutrophils (Canny and Levy, 2008) . The BPI structure shows it is a boomerang-shaped protein consisting of two structurally similar b barrels (Beamer et al., 1998) . Each barrel is made of an antiparallel b sheet with two flanking a helices forming apolar pockets. LBP and BPI have substantial sequence homology but markedly different properties: Whereas BPI neutralizes LPS and has potent bactericidal activity, LBP can transfer LPS to its cell-surface receptor and enhances cellular inflammatory responses to LPS. Mutagenesis and biochemical experiments have revealed distinct roles for the different domains of LBP (Han et al., 1994; Ooi et al., 1987; Schumann et al., 1997) . A truncated form of LBP can bind LPS efficiently but does not transfer it to CD14 and instead inhibits LPSinduced activation of peritoneal macrophages. Therefore, it has been proposed that the LPS-binding site of LBP is located in its N-terminal and the CD14 interaction site in the C-terminal half. However, structural differences between LBP and BPI that might account for their functional differences have not been identified.
Here we describe the crystal structure of LBP at 2.9 Å resolution. The two linker regions between the central and C-terminal domains differed substantially from those of BPI, leading to rearrangement of the C-terminal domain and generating a large groove near the C-terminal phospholipid binding pocket. In addition, a hydrophobic ''phenylalanine core'' was present only (B) The N-terminal and central domains of human BPI and mouse LBP are aligned, and the Ca traces are shown (see also Figure S1 and Table S1 ).
in LBP and not in BPI. We also found a LBP SNP affecting an amino acid in close proximity to this phenylalanine core, which is common in the German population. By computer-modeling, recombinant expression and analyzing sera from individuals differing in LBP genotype, we found major functional differences of the mutant LBP. Finally, by investigating several large patient cohorts, we found that the presence of this LBP variant might influence the clinical course of sepsis and pneumonia.
RESULTS
The Overall Structure of LBP Differs Substantially from that of BPI LBP is a highly extended molecule, 33 Å wide and 127 Å long ( Figure 1A ). It can be divided into three domains, an N-terminal domain (residues 37-214), a central domain (residues 26-36, 215-281 and 451-481) , and a C-terminal domain (residues 282-450). The N-terminal domain has a barrel-shaped structure with a long a-helical backbone, a helix B flanked by a five-stranded b sheet, sheet N, and a shorter helix, helix A, at the N terminus. The central domain consists of a twisted, seven-stranded antiparallel b sheet. The C-terminal domain is topologically similar to the N-terminal domain with the exception that in place of the N-terminal a helix there is a partially disordered loop referred to as the ''A' loop.'' The b sheets in the N-terminal and C-terminal domains contain twisted and bulged antiparallel b strands wrapped around each other to form barrel-like structures. Each of the Nand C-terminal barrels contains a single hydrophobic pocket with a bound phospholipid molecule.
Mouse LBP has 48% sequence identity with human BPI, and there are only four single amino-acid gaps in the aligned sequences (see Figure S1 available online). As predicted from the sequence homology, the individual N-terminal, central, and C-terminal domains of LBP and BPI can be superimposed with Ca root-mean-square (rms) differences of 1.1, 0.5, and 1.2 Å , respectively ( Figure S2 ). However, the complete structures cannot be aligned satisfactorily because of a large displacement of the C-terminal domain of LBP relative to its N-terminal and central domains ( Figure 1B ). This domain displacement derives from a structural transition of the A' helix as seen in BPI into the A' loop of LBP and tilting of the B' helix in the C-terminal domain of LBP (Figure 2 ). This displacement of the C-terminal domain generates a wide, negatively charged groove between the C-terminal and central domains, which is absent in BPI (Figure 3) .
The N-terminal and central domains of LBP are structurally similar to those of BPI. The Ca rms differences are 1.1 and 0.5 Å , consistent with the average structural difference between proteins with 48% sequence identity ( Figures S1 and S2 ). There is experimental evidence that the N-terminal domain is the main site of interaction with LPS , in particular the positively charged residues at its tip. The tip contains conserved residues with either positively charged or moderately hydrophobic side chains, and mutations of residues Arg94, Lys95, and Lys99 in human LBP (which we propose to rename according to Swissprot P18428 Arg119, Lys120, and Lys124) abolish LPS binding ( Figure 3B ). Furthermore, a synthetic peptide containing the N-terminal tip region has LPSblocking activity .
Identification of an A' Loop and Phenylalanine Core within the C-Terminal Domain of LBP The most noticeable structural difference between LBP and BPI is the dramatic shift of the C-terminal domain of LBP relative to that of BPI. This structural rearrangement appears to be induced by a relatively small number of amino acid changes in the A' loop region (Figures  2A-2D ; Figure S3 ) and the loops preceding the B' helix ( Figure 2E-2G ). In BPI, the A' helix connects the central and C-terminal domains and closes the barrel-like structure by joining the b9-and b12-strands of the central and C-terminal domains, respectively (Beamer et al., 1997) . In LBP, it is replaced by a loop, the A' loop, and several strong interactions with b9 and b12 are missing. Because of this, the b9 and b12 strands are separated by approximately 20Å and the internal region of the C-terminal barrel is partially open to solvent ( Figure 2B ). Of the 17 amino acid residues in the A' helix of BPI, eight are changed in LBP ( Figure S3 ). Of these, the Phe293 to Ala conversion appears the most significant; in BPI, Phe293 forms a hydrophobic core with residues Val36, Ile236, Tyr238, Phe259, and Leu289 of the central domain and Phe294, Leu406, and Leu458 of the C-terminal domain ( Figure 2C ), and this phenylalanine residue is changed to alanine or valine in the LBPs of different species ( Figure 2D ; Figure S3 ). The side chains of alanine and valine are too short to penetrate far into the hydrophobic core region and therefore cannot generate strong hydrophobic interactions. Due to the shift of the C-terminal domain of LBP, several interactions at the interface between it and the central domain are affected: In human BPI, Leu364 forms hydrophobic interactions with Phe294, Phe366, Leu357, and Met397 ( Figure 2C ). However, in LBP, Ile348 corresponding to Leu364 is shifted by approximately 12 Å and creates new hydrophobic interactions with Leu358, Phe463, and Leu356 ( Figure 2D ). The position of Leu356 is also shifted in LBP and participates in new hydrophobic interactions with Phe463, Leu391, Ala389, Leu358, and Ile348.
The structural shift of the C-terminal domain of LBP is associated with $10 degree rotation of the B' helix connecting the C-terminal and central domains ( Figure 2E ). This movement appears to be initiated by small structural changes in the loop preceding the B' helix. Conformation of this b15-B' loop is stabi- Of note, the phenylalanine core here consists of only four Phe residues (black). In order to mark other mutations found in this region, the molecule was turned with the A loop marked (red). Several less frequent mutations described in the NCBI database are also marked in red. Marked in bold red are two mutations of interest: one is F436L previously described by others to be of clinical relevance (rs2232618, see text), and the other is a newly identified mutation analyzed by us in more detail affecting amino acid 333 (rs2232613). Note that the latter mutation is in close proximity to the phenylalanine core region. See also Figure S3 .
lized by an unusual hydrophobic core composed of six phenylalanines at positions 321, 324, 379, 419, 424, and 427 (Figure 2F) . This phenylalanine core is absent in BPI because Phe424 and 427 are changed into a leucine and aspartate, respectively. The remaining four phenylalanines of BPI are farther apart as a result of structural changes induced by multiple proline residues. Prolines have restricted backbone conformations due to the cyclic nature of their side chains. Pro426 and Pro428 in BPI pull Phe427, corresponding to Phe419 of LBP, away from the putative phenylalanine core by 2.8 Å ( Figure 2G ). These prolines are replaced by Met418 and Asn420 in LBP. Pro323 of LBP, replaced by Thr331 in BPI, changes the conformation of the loop between the a1 and a2 helices. Because of this, the side chain of Phe324 can penetrate 4.7 Å into the protein core completing the phenylalanine core.
The Structure of the C-Terminal Groove Allows for Modeling of Relevant Mutations found in Human LBP Like BPI, LBP contains two phospholipid binding pockets (Figure 1A) . The N-terminal pocket of LBP with its bound phospholipid is similar to that of BPI. It is formed by the A and B helices, together with the b2-to b6-strands of the N-terminal domain and hydrophobic residues from the b sheet of the central domain. The head group of the phospholipid is exposed to solvent, and the hydrophobic fatty acid chains are buried inside the pocket. The opening of the N-terminal pocket is surrounded by conserved positively charged amino acids interacting with the negatively charged phosphate group of the phospholipid. The phospholipid binding pocket in the C-terminal domain of LBP is different in both shape and size from that of BPI; the pocket of LBP is rotated by $30 degrees relative to the N-terminal pocket ( Figure 1B ), and this domain movement changes the orientation of the C-terminal pocket such that the two pockets point in different directions. Residues from the A' loop, B' helix, and b11-b16 strands form the hydrophobic wall interacting with the fatty acid chain of the phospholipid ( Figure 3B ). Because the head group does not interact effectively with proteins, its conformation is flexible and only barely visible in one of the monomers in the asymmetric crystal unit. The transition of the A' helix to the A' loop rotates the N' beta sheet of the C-terminal domain, and the area occupied by the A' helix and the N' beta sheet in BPI turns into a wide groove in LBP. The phospholipid binding pocket is located at the bottom of the groove and is continuous with the groove. Unlike the area of the N-terminal phospholipid pocket, the surface of the groove is covered with the negatively charged residues Asp223, Glu250, Asp283, Asp305, Asp306, and Asp311, Glu338, Asp439, Glu443, and Asp468 ( Figure 3A) .
In order to investigate whether mutations described for human LBP affect the structures found in LBP, a model of human LBP was created with the crystallography information of murine LBP because murine and human LBP share higher sequence homology as human LBP and BPI ( Figure 3C ). This model was of high quality as described in detail in the Supplemental Experimental Procedures. A mutation affecting amino acid 98 (rs2232582, marked in Figure 3C ) affects an exposed loop and has been described to confer a risk for several infectious and inflammatory diseases (Hubacek et al., 2001) . A synonymous SNP at position 204 also is in close proximity and may be haplotypelinked to functional relevant SNPs (Vollmer et al., 2009) . Within the groove region we focused on two mutations ( Figure 3D , bold red), one being in close proximity to the phenylalanine core, located at the outer surface of the protein and thus potentially accessible by proteinases (residue 333: proline changed to leucine, bold red, Figure 3D , rs2232613). Furthermore, we found a mutation to be located within the identified groove region (residue 436: phenylalanine changed into leucine, rs2232618, bold red, Figure 3D ) (Hubacek et al., 2001) . Other mutations at amino acids 339, 364, or 445 ( Figure 3D , marked red) are very rare, and some are only found in African populations.
Discovery and Frequency of the LBP P333L Mutation (rs2232613) and Potential Structural Consequences
We analyzed LBP serum concentrations by using a commercial ELISA assay in a cohort of over 3,000 German children and detected several individuals with apparently low serum concentrations of LBP. These children were homozygous for the rs2232613 LBP SNP described above ( Figure 3D ), suggesting that the commercial ELISA assay used was unable to detect the LBP mutant resulting from this genetic variation. In a crosssectional population study of 3,061 German children in Munich (n = 1142) and Dresden (n = 1919) (Schedel et al., 2008) , the allelic frequency of this SNP was found to be 0.08 (Table S1 ). In a cohort of healthy adults from Berlin, we observed a similar frequency. Whereas 0.46% homozygous children were detected, no homozygous individuals were found among the 627 healthy adults tested.
Utilizing the homology model, we found aa333, which is highly conserved, to be exposed at the C-terminal tip of the LBP molecule and part of a small helix ( Figure 3D ). An exchange from proline to leucine leads to the generation of a potential cleavage site for the proteases Chymotrypsin, Pepsin und ProteinaseK (Figures 4A and B) . The calculated size of the resulting fragments is 33.9 (for aa1-333), and 15.8 kDa (for aa334-452) adding up to the size of nonglycosylated wild-type (WT) LBP of 49.7 kDa ( Figure 4C ). After cleavage at position 333, disintegration of the two potential LBP fragments would lead to a disruption of both phospholipids binding pockets ( Figure 4D ). This may cause additional structural rearrangements driven by the unfavorable exposure of hydrophobic regions, which dissociation of the two fragments would entail. Even in a nondissociated state, cleavage of the peptide bond at P333 is predicted to result in substantial structural changes as assessed by 10 ns molecular dynamics simulation of human LBP P333L and WT models (Figure S4 ; Supplemental Experimental Procedures). The outer tip of the LBP molecule formed by amino acids 319, 322, 327, and 330 at the C terminus would change its conformation and surface charges in the ''cleaved'' P333L model of human LBP, whereas in WT-LBP side-chain orientation and surface charge remain more stable over the course of the simulation ( Figure S4 ). Thus it is suggested that peptide cleavage results in conformational distortions likely to impact the ability of LBP to bind LPS and/ or LP, and might also affect its serum half-life.
Sera from P333L Carriers Contain Cleaved LBP Next we analyzed sera from individuals genotyped for LBP by Immunoblot ( Figure 4E , left two panels). Sera from P333L carriers were obtained from two individuals carrying the mutation in a homozygous form (7 and 8) and four individuals carrying the heterozygous form (3-6), and were compared to individuals with the ''normal'' LBP genotype (1 and 2). A polyclonal anti-LBP antiserum revealed the typical double band at 58 and 60 kDa known to be caused by two different glycosylation forms of LBP, as expected for the WT individuals ( Figure 4E, left panel) . A similar, weaker signal was also detected in the serum of the heterozygous SNP carriers. In sera from homozygous individuals, almost no bands at 58 and 60 kDa were visible. A second polyclonal antiserum detected an additional band at 23 kDa in sera from individuals homozygous for the rs2232613 SNP (Figure 4E , second panel from left). This size corresponds to the smaller postulated cleavage product (15.8 kDa plus four N-Glycans). The expected larger fragment at 37 kDa was not detected, which might be caused by a lack of reactivity of this fragment with the antisera used, or by subsequent degradation in serum.
Cloning and Expression of the LBP Mutant Reveals Severe Functional Consequences
Next, WT and the c998t mutated LBP prolonged by six histidines (His-Tag) were expressed in HEK293 cells and detected by ELISA analysis, and protein size was analyzed by Immunoblot ( Figure 4E ). For details, see Supplemental Experimental Procedures and Figure S5 . For WT-LBP, a monoclonal antibody detected one band at the expected size of approximately 55 kDa. The recombinant protein did not display a double band and was slightly smaller most likely as a result of different glycosylation as compared to serum-LBP. No band of this size and no other positive signals were detected for the mutant LBP (P333L) ( Figure 4E , right panel). The polyclonal antiserum that detected the small LBP fragment in serum identified two additional bands for the mutant recombinant protein. The first was of similar size as seen in sera from homozygous patients at 23 kDa and the second at 37 kDa matched the hypothetical size of the larger LBP fragment (33.9 kDa plus one N-Glycan), which would be obtained by protease cleavage ( Figure 4E , second panel from the right). Another polyclonal antiserum detected a band at approximately 55 kDa during purification of the mutant recombinant protein ( Figure S5 ). This suggests that the mutated protein is initially expressed in full size and then may be cleaved or degraded. Purification in the presence of proteinase inhibitors did not change the results (data not shown).
P333L LBP Does Not Bind LPS or Induce Cytokines In Vitro
In order to analyze functional differences of LBP from donors differing in their rs2232613 genotype, blood was drawn and serum separated from healthy volunteers genotyped for the LBP mutation. We immobilized LPS and LPs on microtiter plates and inoculated them with the different sera. Binding of LBP to the bacterial ligands was assessed by an ELISA-type assay as described . While sera from individuals WT for the rs2232613 SNP (+/+) bound to both forms of LPS, sera from homozygous mutated individuals (À/À) completely lacked LPS-binding capacity ( Figure 5A , upper panels). Sera from heterozygous individuals (+/À) displayed approximately 50% activity. Similar results, although less pronounced, were obtained for lipopeptides, which also are ligands of LBP (Figure 5A , lower panels): Confirming previous results (Schrö der et al., 2004) , we observed a biphasic dose-response curve for LBP toward LPS recognition, with high concentrations of LBPcontaining serum inhibiting binding of LPS, but not of lipopeptides ( Figure 5A ). Cell supernatants containing mutant and WT-LBP were also tested for their ability to bind to bacterial ligands and we observed a profound difference in the binding capacity between these proteins ( Figure 5B ). Binding of WT-LBP to two types of LPS and LP tested was observed at concentrations of 10-100 ng/ml. In contrast, mutant LBP was unable to bind lipopeptides when these concentrations were applied. LPS binding was impaired, however, some interaction was observed at higher concentrations. Next, the murine macrophage cell line RAW264.7 was stimulated with bacterial ligands in the presence and absence of sera from individuals differing in their LBP genotype ( Figure 6A ), as well as in the presence of the recombinant LBP variants (Figure 6B ). We observed a clear difference for LPS-and diacylated LP-induced cytokine secretion in the presence of 5% serum. Sera from individuals heterozygous for the LBP mutation enhanced mTNF-induction by approximately 50% as compared to sera from WT-LBP individuals. With triacylated LP and 5% sera, however, no difference was visible. With 1% sera, there was a discrete difference as seen for diacylated LP and LPS but less pronounced. mTNF-induction induced by bacterial ligands was enhanced by 100 ng/ml recombinant WT-LBP, whereas cell stimulation in the presence of mutant LBP was 50% or less. Similar results were obtained with only 10 ng/ml of recombinant LBP (data not shown). Identical results were also obtained with the human THP-1 cell line and with freshly isolated human monocytes measuring hIL8-and hTNF-release, respectively (data not shown).
Individuals with the LBP SNP Have Lower Cytokine Concentrations in Serum after Experimental LPS-Application
To ask whether the LBP genotype influences cytokine release induced by LPS in humans in vivo, we analyzed cytokine induction following injection of LPS. A group of 54 healthy volunteers of Caucasian origin were infused with purified LPS prepared from E. coli (O:113, 2 ng/kg) in vivo. Cytokines (TNF and IL-1b) were measured in serum at different time points. All subjects were genotyped for the rs2232613 LBP SNP as described, and 45 were WT and 9 heterozygous corresponding to an allelic frequency of 0.16, which is higher but roughly as expected in Europe. Mean cytokine levels were compared by unpaired t test, to assess the strength of association between the rs2232613 (LBP P333L+/À ) genotype and the inflammatory response. Individuals heterozygous for the LBP mutation showed a slightly diminished response ( Figure S6 ): For TNF release, this difference at 1 hr after LPS injection was significant ( Figure S6A , p = 0.013). The IL-1b release was slightly delayed and diminished without reaching statistical significance (Figure S6B) . For a clear difference, most likely larger groups of individuals have to be included in order to also include homozygous individuals.
LBP SNP Carriers Produce Fewer Cytokines during Pneumonia and Have a More Severe Course of Infection
Serum cytokine concentrations were also assessed in a group of patients originating from Athens, Greece, suffering from ventilator-associated pneumonia caused by Gram-negative bacteria (for details, see Supplemental Experimental Procedures, ''VAP patients''). These individuals were genotyped for the LBP SNP, and of 157 patients, 10 were found to be heterozygous and 2 homozygous for the LBP variant leading to an allelic frequency of 0.07. In vivo TNF-measurement showed that LBP SNP carriers had significantly lower cytokine concentrations (6.2 ± 1.76 pg/ml) as compared to WT individuals (18.4 ± 4.9 pg/ml, p = 0.014). The two homozygous individuals had the lowest TNF concentrations (3.93 ± 1.76 pg/ml) further supporting our in vitro results of LBP being a nonredundant modulator of the systemic in vivo inflammatory response. In another clinical trial with patients going through an acute-phase response, heterozygous LBP SNP carriers exhibited lower cytokine concentrations, and homozygous individuals almost lacked the typical acutephase cytokine induction (data not shown).
To assess the relevance of the LBP rs2232613 SNP for the clinical course of infection, we analyzed a group of 424 patients with a prolonged intensive care unit stay at the Charité , Berlin, Germany (for inclusion criteria, see the Supplemental Experimental Procedures and Kumpf et al., 2010) . Individuals carrying the rs2232613 SNP were compared to WT individuals for the rate and course of infectious complications (Table 1) . Sixtyone SNP carriers were identified, with 57 being heterozygous and 4 homozygous, leading to an allelic frequency of 0.08, similar to the control groups reported here. Comparison of the SNP carrier and the WT group revealed similar disease severity scores on admission, as well as frequencies of infectious complications (Table S2) . Of note, the four individuals homozygous for the LBP SNP investigated all developed infectious complications, and three out of four became septic. Due to the low number, however, no statistical tests could be performed. For the heterozygous individuals, no change in susceptibility for infectious diseases could be detected.
When comparing the course of infectious complications, LBP rs2232613 SNP carriers and homozygous and heterozygous individuals combined exhibited a more severe course of disease, leading to higher mortality rates following sepsis and pneumonia (Table 1 of the SNP carriers and the WT group, however, revealed differences in the incidence of comorbidities: The strongest influence was recorded with renal and hepatic disease, but these were rare and equally distributed over the study cohorts. Unevenly distributed comorbidities had no influence on mortality. This is shown in detail in the Supplemental Information (Table  S2) . Analyzing the course of disease over time, as early as 20 days after onset of the infectious complications, mortality rates were higher among SNP carriers, as shown for patients with pneumonia and pneumonia caused by Gram-negative bacteria ( Figure S7 ). The multivariate analysis in this study does not conclusively reveal why patients in the SNP carrier group had a less favorable outcome. In another trial, 197 patients with community-acquired pneumonia (CAP) caused by S. pneumoniae were analyzed, and individuals heterozygous for the LBP rs2232613 SNP displayed similar mortality rates as compared to WT individuals (9 versus 8%; data not shown). Although a less pronounced effect for LBP toward recognition of S. pneumoniae as compared to Gram-negative bacteria is reasonable, study numbers are still too low to draw definitive conclusions. 
DISCUSSION
In this report, we present the first crystal structure of LBP and report on a frequent genetic variation altering its structure leading to a dysfunctional LBP. We furthermore present evidence that this variation leads to an altered cytokine response and that carriers of this mutation have an increased risk for a more severe course of clinical infections. These results show that structural integrity of LBP is crucial for the host for successful cytokine induction following bacterial stimulation and potentially for fighting infectious diseases.
Solving of the LBP structure reveals that the C-terminal hydrophobic pocket differs structurally from that found in BPI and from models suggested for LBP. The transition of the A' helix to the A' loop in LBP disrupts interactions at the interface between the C-terminal and the central domain, and the closed, barrel-like structure is partially open to the solvent area. This change generates a negatively charged groove at the interface between the central and C-terminal domains in LBP, the function of which is currently unknown. This unexpected domain, and the fact that the mutation described here affects this region, might provide new clues to the different properties of BPI and LBP. Both proteins can bind LPS with nanomolar affinity, but only LBP can transfer LPS to membrane-bound or soluble CD14 (Beamer et al., 1998) and subsequently to the MD-2-TLR4 complex. Because the formation of the groove is the most dramatic structural change in the C-terminal domain, and groove-like structures are frequently found at protein interaction sites, it might be the site of interaction with CD14 and mediate LPS transfer to MD-2-TLR4. Mutagenesis experiments should allow this idea to be tested.
The genotyping data and cytokine measurements suggest that a frequent genetic variation causes the protein to be dysfunctional, altering its induction of a cytokine response in vivo. Although the clinical data have to be confirmed by larger trials, we present evidence that heterozygosity for this mutation is a risk factor for a more severe course of clinical infections. In addition, more complex genotyping strategies might be advisable, including genome-wide association studies (GWASs). Our results suggest the lung as an organ affected by mutation carriers, and this is supported by a recent GWAS analysis performed in Korea, in which copy-number variations (CNV) of genes were related to clinical pulmonary function data of patients. The authors found five gene clusters correlating with pulmonary function, and among these, the genes of the LBP/ BPI/Plunc superfamily obtained the highest score (Lee et al., 2011) . Although it is not clear whether other proteins of this cluster are functionally relevant too, this technique potentially supports our finding that variations of LBP are crucial for lung function in vivo.
Our results suggest that the LBP mutation results in a diminished inflammatory response after bacterial challenge. One explanation for a less favorable outcome during disease is that the amino acid exchange at position 333 of LBP leads to a reduced ability to recognize pathogenic bacteria via LPS or lipopeptides. This might lead to a reduced cytokine response of the host resulting in a weakened defense during infections. In line with this, the phenotype of individuals carrying the rs2232613 SNP resembles our own early observations from the Lbp knockout (k.o.) mouse (Wurfel et al., 1997) : Whole blood from mice lacking LBP was less responsive to LPS in regards to TNF release, and exogenous recombinant LBP was able to restore this reactivity. The differences in the in vivo responses to LPS injection, however, were less pronounced, correlating with the data presented here with human volunteers receiving LPS intravenously: During experimental endotoxemia, individuals carrying the LBP mutation exhibited only a slightly reduced cytokine response when compared to the LBP WT individuals.
The Lbp k.o. mouse is severely diminished in cytokine response to LPS (and thus ''protected'' from its lethal effects), but exhibits increased lethality upon bacterial stimulation (Branger et al., 2004; Jack et al., 1997) . The mutation described here might lead to a similar mechanism because our results also point to an increased lethality during infections combined with a diminished cytokine response. Further supporting this interpretation, in Lbp k.o. mice bacterial overgrowth was found in infection models, paralleled by a lack of innate immune responses (Yang et al., 2002) . In mice, this phenotype could be reverted by a ''gene-therapy'' approach aimed at overexpressing LBP in the lungs (Hemmila et al., 2006) . Our clinical data have to be confirmed by larger trials before a treatment with LBP should be considered for improving outcome during clinical infections.
In certain experimental models, an ''overwhelming'' cytokine induction by LPS also contributes to lethality, and anti-LBP-antibodies aimed at blocking the LBP-mediated cytokine release were beneficial (Le Roy et al., 1999) . One clinical study found that genetic variations within the LBP promoter leading to higher LBP concentrations correlated with susceptibility to Gram-negative infections and worse outcome (Chien et al., 2008) . These findings underscore the importance of LBP and its genetic variations and might reflect on the known biphasic dose-response curve of LBP with both, absence, and high concentrations of LBP leading to a reduced immune response (Lamping et al., 1998) . It has been proposed that during severe clinical infections, both, a proinflammatory, and an anti-inflammatory phase exist, and that a prolonged anti-inflammatory phase may be detrimental (Kumpf et al., 2010; Muenzer et al., 2010) . LBP can also inhibit the inflammatory response; for example, high concentrations of LBP in the presence of serum lipoproteins can block LPS-responses and protect mice in disease models (Hamann et al., 2005; Lamping et al., 1998; Vreugdenhil et al., 2003; Zweigner et al., 2001 ). This LBP function of LPS-detoxification might be also impaired in SNP carriers; however, our experimental systems were not sufficient to investigate this. LPSdetoxification and subsequent inhibition of inflammation is particularly important for pulmonary LBP because it has been shown to protect from the effects caused by Gram-negative or -positive bacteria, or both (Knapp et al., 2006; Mueller et al., 2006) .
In a recent clinical trial, genetic variations in the promoter region of the LBP gene have been linked to sepsis incidence In a retrospective analysis, 424 patients that underwent major surgery with a prolonged ICU stay (for details see Experimental Procedures and Supplemental Information) were analyzed for clinical outcome. DNA was analyzed for presence of the rs2232613 LBP SNP, and clinical data were related to the genotype. There was a trend toward higher mortality in individuals heterozygous or homozygous for the rs2232613 SNP (11% versus 6% mortality). A significant correlation was seen among patients either suffering from sepsis or pneumonia caused by Gram-negative bacteria. Among these groups, more individuals mutated for LBP died as compared to WT individuals. See also Figure S7 and Tables S2 and S3 (Flores et al., 2009 ). The authors genotyped their patients for a number of SNPs and identified a haplotype block linked to sepsis susceptibility; however, they did not include the rs2232613 LBP SNP in their analysis. Furthermore, the patients' inclusion criteria differed from ours, so it could not serve as confirmatory group for our study. Only a subgroup of this cohort were postsurgical patients comparable to the cohort of this study, and within this small group a linkage of the rs2232613 LBP SNP (occurring less frequently in Spain; allelic frequency: 0.05) with pulmonary infection caused by Gram-negative bacteria was found when we reanalyzed the Spanish samples (data not shown). However, the small patient number did not allow for the statistical analysis. Recent studies have linked LBP variations present in Asia with inflammatory diseases: Takeuchi et al. found that within a region claimed to contain susceptibility genes for type 2 diabetes, it is LBP and its variations that contributes to disease risk (Takeuchi et al., 2007) . Other inflammatory diseases such as atherosclerosis and metabolic syndrome have also recently have been linked to LBP: LBP concentrations correlate with metabolic syndrome, and a genetic variation in aa436 (rs2232618) showed a weak correlation with LBP concentrations (Gonzalez-Quintela et al., 2013 ). An increased risk for myocardial infarction was seen earlier when mutations in LBP at either amino acid 98 or 436 are present (Hubacek et al., 2002) . The same mutations recently were found to correlate with the degree of atherosclerosis in a cerebral infarction cohort as measured by intima-media thickness (IMT) (Zhan et al., 2012) . Of note, the LBP rs2232618 mutation affecting aa436 found to correlate with metabolic syndrome and atherosclerosis, by the structural data presented here was confirmed to be located at a central position close to the newly identified ''groove'' region.
In conclusion, we found a large structural difference between the C-terminal domains of LBP and BPI. This difference appears to be due to only a few amino acid changes in the linker regions between the central and C-terminal domains. The structural shift of the C-terminal domain in LBP generates a negatively charged groove in the interface between the central and C-terminal domains that might play an important role in the LPS transfer reaction. We identified a frequent LBP mutation affecting this region, leading to an altered function of this protein with potential clinical consequences particularly during sepsis and pneumonia. The exact role of this mutation in vivo currently cannot be completely elucidated because LBP might also play a role in inflammatory diseases affecting overall clinical outcome. The mutant LBP described here has impaired ligand-binding and cytokine-induction function, and the presence of this genetic variation is associated with lower amounts of cytokine induction in vitro, and also in vivo, during experimental endotoxemia and infection. Our retrospective clinical analysis proposes that individuals carrying this mutation are at risk for fatal sepsis and pneumonia, although these results have to be confirmed in larger trials. These findings might have consequences for individual patient's risk assessment, and support the concept of LBP as key mediator of the inflammatory response. The results might furthermore improve our understanding of the complex LPS-recognition machinery and could potentially help in the development of novel immunomodulatory therapies.
EXPERIMENTAL PROCEDURES Expression and Purification of Recombinant Murine LBP for Crystallization
The cloned plasmid containing the murine LBP sequence was cotransfected with Baculogold (BD Biosciences) into SF9 insect cells as described in the manufacturer's protocol. To produce the protein, we cultured Hi Five insect cells in SF900II serum-free medium (both: GIBCO/Invitrogen) and incubated them for 3 days with the recombinant virus. The secreted LBP with the Histidine tag was purified by SP-Sepharose Fast Flow ion-exchange chromatography (GE Healthcare Life Sciences). The fractions containing LBP identified by SDS-PAGE were then loaded onto a Ni-NTA (Peptron) affinity column and eluted with 0.5 M imidazole, pH 7.0. The fusion protein was purified by Superdex-200 gel filtration chromatography (GE Healthcare Life Sciences). LBP-containing fractions were pooled and concentrated to 10 mg/ml for crystallization.
Crystallization, Data Collection, Structure Determination, and Refinement Crystals were grown by hanging drop vapor diffusion with 25% PEG 8,000 and 100 mM MOPS (pH 6.5) at 22 C. Diffraction data were collected at the BL41XU beam line of SPring-8 and the 4A beamline of the Pohang Accelerator Laboratory with crystals flash-frozen at À170 C in the crystallization buffer supplemented with 30% glycerol. Diffraction data were processed with the HKL2000 package (Table S4 ) (Otwinowski and Minor, 1997) . Initial phases were obtained by molecular replacement technique with the reported BPI structure as a search model (Beamer et al., 1997) . Molecular replacement calculation with the complete structural model of BPI did not give an acceptable solution probably as a result of the extensive structural shift of the C-terminal domain. Therefore, the probe structure was divided into N-terminal, central, and C-terminal domains, and a reasonable solution was obtained with the program PHASER (McCoy et al., 2005) . The initial electron density map was calculated to 2.9 Å , and repeated cycles of refinement and model building with CNS and O were performed (Brü nger et al., 1998; Jones et al., 1991) . The final model contained two protein molecules in the asymmetric unit. We found three glycosylation sites in each protein monomer in the C-terminal domain and assessed the quality of the final model with the program PROCHECK (Laskowski et al., 1993) .
SNP Genotyping
The LBP rs2232613 SNP (c998t) was determined by real-time PCR assays with subsequent melting curve analysis with a LightCycler 1.5 (Roche Diagnostics). The PCR reaction was as follows: One reaction volume of 20 ml contained 2 ml 103 PCR Buffer, 2 mM MgCl 2 , 125 mM NTPs, 5 U Taq polymerase, 3 mg BSA, primers at 0.5 mM ( Table 2 for oligonucleotides use for genotyping LBP c998t. including sodium pyruvate and 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 200 mM L-glutamine. Transfection was maintained by the addition of Hygromycin B (PAA). Cells were cultured at 37 C in 5% CO 2 , 95% air humidified incubators. Supernatants containing the recombinant proteins were collected continuously and stored at À20 C.
LBP Immunoblotting
Samples containing LBP were resolved by SDS-PAGE under reducing conditions (12.5% resolving gel) and transferred onto PVDF (Immobilon-P, Millipore). The membrane was blocked for 1 hr in 5% dried skim milk in Phosphate-buffered saline (PBS). LBP was probed with different primary antibodies (obtained from Abcam, Xoma, R&D Systems, and Biometec) for 1 hr in PBS containing 5% dried skim milk. After extensive washing, the membrane was incubated for 1 hr with the secondary horseradish peroxidase (HRP)-conjugated antibody (Santa Cruz Biotechnology). See Table 3 for antibodies.
Binding Assay for Bacterial Ligands
Microtiter plates were coated with triacylated or diacylated LPs (Pam 3 CysSK 4 or Pam 2 CysSK 4 , respectively) (EMC microcollections) and LPS derived from E. coli O111:B4 or S. minnesota Re595 (Sigma) at 30 mg/ml in 100 mM Na 2 CO 3 (pH 9.2) for 6 hr at room temperature. Blocking was performed with 150 mM NaCl and 50 mM HEPES (pH 7.4) supplemented with 10 mg/ml BSA (Carl Roth GmbH) for 30 min at room temperature. Plates were then incubated with rhLBP from cell supernatant or with human sera at increasing concentrations in the same buffer supplemented with 1 mg/ml BSA at room temperature for 2 hr. LBP was detected by the monoclonal antibody bIG48 (Biometech) (1 mg/ml) and streptavidin-coupled horse radish peroxidase. Detection of the cytokines took place with a chromogene substrate solution (TMB, Seramun). The photometric reaction was stopped with 1M H 2 SO 4 and measured at OD 450 nm in an ELISA-reader (TECAN).
Berlin Patient Characteristics
Patients were treated at the ICU of the Robert-Rö ssle-Klinik of the Charité -University Medical Center, Berlin, Germany, between 1999 and . Inclusion criteria were a prolonged length of stay of >7 days or premature death following surgery indicating a complicated course. Case histories were examined for development of infectious complications and associated medical conditions. Prior to surgery, sampled blood or tissue specimens were examined for the LBP SNP. The study was approved by the local Ethics committee, and DNA testing was permitted by a signed broad written consent including DNA testing before surgery. All steps were performed according to the Helsinki declaration. Further information for this cohort and the Athens trial on VAP can be obtained in the Supplemental Information and in a previously published study (Kumpf et al., 2010) .
Statistical Analysis
Mean cytokine levels were compared by the unpaired t test. For group comparison the c 2 test or Fisher's exact test were employed. Odds ratios (OR) were calculated by cross tabulation and c 2 test and are reported with a 95% confidence interval (CI). Influence of comorbidities was tested with binary logistic regression. For survival analysis, the Kaplan-Meier survival analysis with log-rank statistics was used. A two-tailed p value < 0.05 was considered statistically significant. Statistical analysis was carried out after anonymization of the patient's data. For statistical analysis, either the software packages SPSS Version 14.0 (SPSS) or Prism Version 4.0 or 5.0 (GraphPad) were used.
ACCESSION NUMBERS
The accession code for coordinates and diffraction data for the LBP structure in this paper is 4M4D. anti-rabbit IgG, 1:10,000
SUPPLEMENTAL INFORMATION
Polyclonal antibody II (Xoma) from rabbit, 1:2,000
anti-rabbit IgG, 1:20,000
Polyclonal antiserum (R&D) from goat, 1:250
anti-goat IgG, 1:5,000
Monoclonal antibody biG42 (Biometech) from mouse, 1:2,000
anti-mouse IgG, 1:10,000
Antigens were detected with enhanced chemiluminescence (Super Signal West Pico Chemiluminescent Substrate, Thermo Fisher Scientific). For reprobing, blots were stripped with Restore Immunoblot Stripping Buffer (Thermo Fisher Scientific) for 15 min at room temperature.
